CervoMed (CRVO)
NASDAQ:CRVO
Want to see CRVO full AI Analyst Report?
Top Page
CervoMed
(NASDAQ:CRVO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.00
▲(0.50% Upside)
Action:ReiteratedDate:04/23/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and accelerating cash burn) and a bearish technical setup (below key moving averages with negative MACD). Positive clinical and program milestones provide upside potential but are tempered by the company’s funding needs, while valuation signals are limited due to a negative P/E and no dividend.
Positive Factors
Phase 3 progression backed by MRI efficacy signal
Placebo-controlled MRI evidence of increased basal forebrain volume and the company plan to start a Phase 3 in H2 2026 provide a durable development milestone. A biomarker-linked structural signal strengthens the mechanistic case, improves regulatory engagement prospects, and materially de-risks late-stage development if replicated.
Negative Factors
Accelerating cash burn
Operating cash flow has worsened substantially, indicating heavier ongoing cash requirements. Sustained and accelerating burn elevates near-term financing needs, increases vulnerability to market conditions, and creates execution risk for expensive Phase 3 activities absent secured funding or partner support.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 progression backed by MRI efficacy signal
Placebo-controlled MRI evidence of increased basal forebrain volume and the company plan to start a Phase 3 in H2 2026 provide a durable development milestone. A biomarker-linked structural signal strengthens the mechanistic case, improves regulatory engagement prospects, and materially de-risks late-stage development if replicated.
Read all positive factors
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.46M
Dividend YieldN/A
Average Volume (3M)112.80K
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue Growth-58.86%
EPS Growth-47.17%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.97
Shares Outstanding9,258,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)17.83
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue84.40
Enterprise Value/Gross Profit84.40
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$20.80Price Target Upside422.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.35
Revenue Forecast (FY)$425.00K
CervoMed Business Overview & Revenue Model
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the trea...
How the Company Makes Money
As a clinical-stage biotechnology company, CervoMed does not typically generate recurring product revenue and primarily funds operations through capital-raising activities. Based on publicly available high-level information, specific, itemized rev...
CervoMed Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.29M | -18.23M | -7.81M | -5.80M | -15.94M |
| Net Income | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | |||||
| Total Assets | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | |||||
| Free Cash Flow | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
Negative
3.98
Price Trends
4.30
Negative
5.97
Negative
7.12
Negative
Market Momentum
-0.11
Negative
45.84
Neutral
52.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Negative. The current price of 3.98 is above the 20-day moving average (MA) of 3.96, below the 50-day MA of 4.30, and below the 200-day MA of 7.12, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 45.84 is Neutral, neither overbought nor oversold. The STOCH value of 52.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRVO.
CervoMed Risk Analysis
CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CervoMed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $304.93M | -2.77 | -129.98% | ― | 73.43% | 25.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $398.23M | -6.44 | -115.27% | ― | 1273.21% | 21.69% | |
45 Neutral | $27.98M | -6.26 | -88.89% | ― | -100.00% | 21.87% | |
44 Neutral | $35.46M | -2.26 | -96.04% | ― | -58.86% | -47.17% | |
42 Neutral | $26.51M | -0.96 | -191.12% | ― | ― | 5.45% |
* Healthcare Sector Average
CRVO
CervoMed
3.83
-5.08
-57.01%
XFOR
X4 Pharmaceuticals
4.38
1.14
35.19%
ABVC
ABVC BioPharma
1.10
-0.17
-13.39%
JSPR
Jasper Therapeutics
0.95
-3.37
-78.10%
PRLD
Prelude Therapeutics
4.84
4.08
536.84%
ESLA
Estrella Immunopharma
1.30
0.18
16.07%
CervoMed Corporate Events
Business Operations and Strategy
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
Positive
Apr 22, 2026
On April 22, 2026, CervoMed reported Phase 2b RewinD-LB trial data presented at the American Academy of Neurology meeting showing that neflamapimod increased basal forebrain volume and enhanced functional connectivity in patients with dementia wit...
Business Operations and StrategyProduct-Related Announcements
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia
Positive
Apr 7, 2026
On April 7, 2026, CervoMed announced that its representatives would present key aspects of the neflamapimod clinical program at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, highlighting clinical findings, global regulatory al...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed Posts Investor Presentation Under Regulation FD Disclosure
Neutral
Mar 23, 2026
CervoMed Inc. has posted an investor presentation on its website under the Investors – Events and Presentations section, outlining summary information about its business, clinical studies, development plans and financial position intended to...
Business Operations and Strategy
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results
Positive
Mar 19, 2026
On March 19, 2026, CervoMed reported new analyses from its Phase 2b RewinD-LB trial showing that DLB patients with lower plasma pTau181 levels, indicating absence of Alzheimer’s co-pathology and earlier-stage disease, experienced greater cli...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
CervoMed Reports 2025 Results, Advances Neflamapimod Programs
Neutral
Mar 17, 2026
On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its neflamapimod pipeline, highlighting positive Phase 2b RewinD-LB data in dementia with Lewy bodies presented in 2025 and regulatory alignment wi...
Business Operations and StrategyProduct-Related Announcements
CervoMed Advances Neflamapimod With Phase 1 Completion
Positive
Mar 4, 2026
On March 4, 2026, CervoMed reported completion of a Phase 1 healthy volunteer study assessing the pharmacokinetics of a new, stable crystal form of its lead drug neflamapimod, manufactured via a controlled process to avoid prior polymorph-related ...
Business Operations and Strategy
CervoMed’s Neflamapimod Added to U.K. ALS Platform
Positive
Feb 18, 2026
CervoMed Inc., a U.S.-based clinical-stage biotechnology company listed on Nasdaq, develops oral small-molecule therapies for age-related neurodegenerative disorders, led by neflamapimod. The drug candidate targets p38 MAP kinase–mediated ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.